Press release
MDM2 Protein Inhibitors Therapeutics, Clinical Trials & Results, Pipeline Analysis 2019 | Top players Daiichi Sankyo, Inc., Aileron Therapeutics, Amgen, Roche
Download the sample report @ https://www.pharmaproff.com/request-sample/1205
MDM2 protein therapies have shown positive clinical results for the treatment of various cancers. Also, researches have demonstrated that additional biomarkers are required to be identified to increase the chances of clinical success as mutations in p53 can lead to resistance to MDM2 inhibitors.
Get the detailed analysis @ https://www.pharmaproff.com/report/mdm2-protein-inhibitors
Daiichi Sankyo Company Limited is in the process of developing DS-3032 as a proto-oncogene protein C MDM2 inhibitor for the treatment of leukemia, and solid cancers. Some of the other companies having pipeline of MDM2 protein inhibitors include Aileron Therapeutics Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd.
Request for customization @ https://www.pharmaproff.com/request-customization/1205
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MDM2 Protein Inhibitors Therapeutics, Clinical Trials & Results, Pipeline Analysis 2019 | Top players Daiichi Sankyo, Inc., Aileron Therapeutics, Amgen, Roche here
News-ID: 1681570 • Views: 199
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for MDM2
Want to know positive clinical results of MDM2 Protein Inhibitors Therapeutics? …
MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the…
Liposarcoma Therapeutics, Clinical Results, Designations, Collaborations, Licens …
Liposarcoma is a type of tumour that arises from fat tissues in thighs, legs, abdomen, and retroperitoneum. Liposarcoma is also considered as malignant tumour because it spread to surrounding organs. According to the World Health Organization, liposarcoma is characterized into five types including, myxoid, well differentiated, dedifferentiated, round cell, and pleomorphic. Liposarcoma is generally observed as painless enlarged mass.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/liposarcoma-therapeutics-pipeline-analysis
It affects men and women equally. Well…
In Depth Research on Oncogene Inhibitors Market & Pipeline Insight 2015
" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight:
* Global Oncogene Inhibitors Market Overview
* Oncogene Inhibitors Pipeline by Company, Indication & Phase
* Oncogene Inhibitors Pipeline: 185 Drugs
* Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs
* Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs
* Proto Oncogene Protein c-akt Inhibitors: 39 Drugs
* Marketed Oncogene Inhibitors: 22 Drugs
* Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs
For Report Sample Contact: neeraj@kuickresearch.com …
In Depth Research on Cancer Targeted Therapy Market & Clinical Insight 2015
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
* Introduction & Categorization of Cancer Targeted Therapies
* Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
* Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
* Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
* Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
* Global Cancer Targeted Therapeutics Market Dynamics
* Future Prospects of Cancer Targeted…
Oncogene Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2015
Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and…
Cancer Targeted Therapy Market Sales Revenue Clinical Trials Pipeline Report 201 …
Cancer targeted therapy global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug…
